A Randomized, Double Blinded, Study of Two Different Dose Combinations of Nivolumab in Combination with Ipilimumab in Subjects with Previously Untreated, Unresectable or Metastatic Melanoma

Recruitment & Eligibility

Status: ot Recruiting

Sex: All

Target Recruitment: 385

Inclusion Criteria

-Adult subjects (>=18 years) with histologically confirmed unresectable
Stage III or Stage IV Melanoma as per AJCC staging system.
-Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
-No prior systemic anticancer therapy for unresectable or metastatic
melanoma. Prior adjuvant or neoadjuvant melanoma therapy ispermitted if it was completed at least 6 weeks prior to date of first dose,
and all related adverse events have either returned to baseline or
stabilized.
-Measurable disease as per Response Evaluation Criteria in Solid Tumors
version 1.1 (RECIST) criteria
-Tumor tissue from an unresectable or metastatic site of disease must be
provided for biomarker analyses. In order to be randomized, a subject
must be classified as PD-L1 positive, PD-L1 negative, or PD-L1
indeterminate. If an insufficient amount of tumor tissue from an
unresectable or metastatic site is available prior to the start of the
screening phase, subjects must consent to allow the acquisition of
additional tumor tissue for performance of biomarker analyses.
-Known BRAF V600 mutation status as determined by local institutional
standard or subject to consent to BRAF V600 mutation testing per local
institutional standards during the Screening Period, the results of which
must be reported within 3 months of randomization. All BRAF statuses
(BRAF wild-type or BRAF 600 mutation positive) are eligible.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 322
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 138

Exclusion Criteria

- Active brain metastases or leptomeningeal metastases. Subjects with
brain metastases are eligible if these have been treated and there is no
evidence of progression via magnetic resonance imaging (MRI, except
where contraindicated in which CT scan is acceptable) for at least 8
weeks after treatment is complete and within 28 days prior to first dose
of study drug administration. There must also be no requirement for high
doses of systemic corticosteroids that could result in
immunosuppression (> 10 mg/day prednisone equivalents) for at least 2
weeks prior to study drug administration.
-Ocular melanoma
-Subjects with active, known or suspected autoimmune disease.
Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism
due to autoimmune condition only requiring hormone replacement,
psoriasis not requiring systemic treatment, or conditions not expected to
recur in the absence of an external trigger are permitted to enroll

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials